Alkylating Derivatives of Vitamin D Hormone for Prostate Cancer

Abstract

The first significant achievement during this period includes strongly encouraging results of cellular studies with prostate cancer cells to demonstrate that a combination of 1,25-dihydroxyvitamin D3-3-bromoacetate (1,25(OH)2D3-3-BE) and another compound named Largazole synergistically reduced the growth of these cells. Combination therapy in cancer is a well recognized modality in cancer-treatment. Therefore these results are highly significant in moving our drug (1,25(OH)2D3-3- BE), forward for prostate cancer-treatment. The second achievement involves development of a liposomal preparation of 1,25(OH)2D3-3-BE, and demonstration that this preparation is superior to "naked" drug both in in vitro and in vivo assays.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2009
Accession Number
ADA513335

Entities

People

  • Rahul Ray

Organizations

  • Boston University

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Anatomy
  • Androgens
  • Biomedical Research
  • Body Weight
  • Cells
  • Demonstrations
  • Molecules
  • Neoplasms
  • Perchloric Acid
  • Prostate
  • Prostate Cancer
  • Scintillation Counters
  • Small Molecules
  • Synthetic Membranes
  • Thymidines
  • Vitamin D

Fields of Study

  • Medicine

Readers

  • Molecular Biology and Genetics
  • Oncology (Cancer Research).